English
Back
Open Account
牛牛名人追蹤
wrote a column ·

Tracking Cathie Wood: Aggressively buying gene-editing companies CRSP and BEAM while selling Illumina

On Wednesday (January 28), the three major U.S. stock indexes closed mixed. The S&P 500 Index fell 0.01% to 6,978.03 points, briefly surpassing the 7,000-point mark during early trading, reaching a high of 7,002.28 points, setting a new intraday record.
ARK executed a textbook 'sector rotation' in last night’s trading session. Rather than a routine rebalancing, this move was more like Cathie Wood casting a renewed vote on the growth logic of the biotech industry by 2026.
On Wednesday (January 28), the three major U.S. stock indexes closed mixed. The S&P 500 Index fell 0.01% to 6,978.03 points, briefly surpassing the 7,000-point mark during early trading, reaching a high of 7,002.28 points, setting a new intraday record. ARK executed a textbook 'sector rotation' in last night’s trading session. Rather than a routine rebalancing, this move was more like Cathie Wood casting a renewed vote on the growth logic of the biotech industry by 2026. Increased position direction: Aggressively going long on the application layer of 'gene editing' Cathie Wood increased holdings $CRISPR Therapeutics (CRSP.US)$ by 118,800 shares, $Beam Therapeutics (BEAM.US)$ 116,400 shares, $Intellia Therapeutics (NTLA.US)$ and 71,800 shares. These three companies represent the cutting edge of gene-editing technology (CRISPR-Cas9 and base editing). Cathie Wood's 'aggressive buying' typically signals that she expects significant clinical data releases soon or believes that valuations in the sector have become extremely attractive. In addition, Cathie Wood continues to implement the integration logic of 'AI + healthcare,' adding positions $Tempus AI (TEM.US)$ , leveraging data advantages to accelerate drug discovery....
Increased position direction: Aggressively going long on the application layer of 'gene editing'
Cathie Wood increased holdings $CRISPR Therapeutics (CRSP.US)$ by 118,800 shares, $Beam Therapeutics (BEAM.US)$ 116,400 shares, $Intellia Therapeutics (NTLA.US)$ and 71,800 shares. These three companies represent the cutting edge of gene-editing technology (CRISPR-Cas9 and base editing). Cathie Wood's 'aggressive buying' typically signals that she expects significant clinical data releases soon or believes that valuations in the sector have become extremely attractive.
In addition, Cathie Wood continues to implement the integration logic of 'AI + healthcare,' adding positions $Tempus AI (TEM.US)$ , leveraging data advantages to accelerate drug discovery.
Direction of reduction: Decisively cutting positions – "Selling the shovel"
ARK significantly reduced its holdings by 59,100 shares on the same day. $Illumina (ILMN.US)$ As the monopolistic leader in gene sequencing equipment, Illumina was once ARK's cornerstone. This "sell upstream equipment, buy downstream therapies" move indicates that ARK is increasing its risk appetite. She may believe that the story of declining sequencing costs has run its course and that future explosive growth will lie in the commercialization of therapies.
Futubull's [Opportunities Page] has launched tracking for celebrity portfolio opportunities! Choose from multiple celebrity portfolios, follow the masters' strategies with one click, precisely lock onto high-quality targets, and invest with greater confidence!
On Wednesday (January 28), the three major U.S. stock indexes closed mixed. The S&P 500 Index fell 0.01% to 6,978.03 points, briefly surpassing the 7,000-point mark during early trading, reaching a high of 7,002.28 points, setting a new intraday record. ARK executed a textbook 'sector rotation' in last night’s trading session. Rather than a routine rebalancing, this move was more like Cathie Wood casting a renewed vote on the growth logic of the biotech industry by 2026. Increased position direction: Aggressively going long on the application layer of 'gene editing' Cathie Wood increased holdings $CRISPR Therapeutics (CRSP.US)$ by 118,800 shares, $Beam Therapeutics (BEAM.US)$ 116,400 shares, $Intellia Therapeutics (NTLA.US)$ and 71,800 shares. These three companies represent the cutting edge of gene-editing technology (CRISPR-Cas9 and base editing). Cathie Wood's 'aggressive buying' typically signals that she expects significant clinical data releases soon or believes that valuations in the sector have become extremely attractive. In addition, Cathie Wood continues to implement the integration logic of 'AI + healthcare,' adding positions $Tempus AI (TEM.US)$ , leveraging data advantages to accelerate drug discovery....
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
8
Heart
1
159K Views
Report
Comments
Write a Comment...
9
24